WebJan 7, 2024 · BioVentrix has announced that heart failure specialist Jerry Estep (Cleveland Clinic, Cleveland, USA) has been appointed as co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using the Revivent TC transcatheter ventricular enhancement system. He joins co-principal investigators Gregg Stone of New York’s Mount Sinai … WebMar 15, 2024 · BioVentrix®, Inc. today announced the publication of a peer-reviewed paper in the Journal of Clinical Medicine, titled, Inward Displacement, A Novel Approach to …

FDA Agrees to Expanded Access Program for the BioVentrix® …

WebApr 13, 2024 · BioVentrix recently received approval from the U.S. Food and Drug Administration for an Expanded Access Program following the successful completion of enrollment in ALIVE, a prospective, multi-center, dual-arm pivotal study. The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a … Web1 day ago · BioVentrix recently received approval from the U.S. Food and Drug Administration for an Expanded Access Program following the successful completion of enrollment in ALIVE, a prospective, multi ... early lead bullets were cast

Andera Partners leads funding for medical device firm BioVentrix

Web1 day ago · BioVentrix recently received approval from the U.S. Food and Drug Administration for an Expanded Access Program following the successful completion of enrollment in ALIVE, a prospective, multi ... Web1 day ago · BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most … WebStudy Name: ALIVE. Study Objective: To evaluate safety/efficacy of a new device, called the BioVentrix Revivent TC System, designed to treat LVA. Key Inclusion Criteria: Age … cstring char 変換